Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT05429190 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Validation of SMS Protocol for HCC Screening in High-risk Patients

Start date: November 7, 2023
Phase:
Study type: Observational

The investigators will assess implementation of the proposed SMS protocol as a surveillance tool in patients at high risk of developing HCC in a prospective multicenter study.

NCT ID: NCT05396118 Enrolling by invitation - Breast Cancer Clinical Trials

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Start date: May 18, 2022
Phase: Phase 2
Study type: Interventional

Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner in patients with cancer.

NCT ID: NCT05349890 Enrolling by invitation - Clinical trials for Malignant Epithelial Neoplasms

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I/Ib study of adoptively transferred T-cell receptor gene-engineered T cells (TCR-T) targeting tumor-specific antigens, with in vivo CD40 activation and PD-1 blockade, for patients with incurable cancers. The study design is a safety lead-in TCR-T with CD40/PD-1 (3+3), followed by Simon's Two-Stage expansion design, 80% power and 5% one-sided alpha: stage-one futility assessment at n = 10; stage-two assessment at n = 22, (accrual up to 24 to allow for potential study drop-out).

NCT ID: NCT05263362 Enrolling by invitation - Breast Cancer Clinical Trials

An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)

STARLINGS
Start date: April 11, 2022
Phase:
Study type: Observational

To assess the role of different combinations of (oncoplastic) surgery and radiotherapy techniques as risk factors for moderate to severe fibrosis and for moderate to poor cosmetic outcome.

NCT ID: NCT05171335 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Start date: June 20, 2022
Phase: Phase 2
Study type: Interventional

This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, and exploratory data will be compared to a matched, retrospective cohort.

NCT ID: NCT05117957 Enrolling by invitation - Clinical trials for Advanced Hepatocellular Carcinoma

Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study

Start date: February 8, 2022
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of sorafenib administered as later lines of treatment in patients with advanced HCC.

NCT ID: NCT05060471 Enrolling by invitation - Anal Cancer Clinical Trials

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Start date: September 8, 2021
Phase: Phase 2
Study type: Interventional

Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Treatment outcomes and toxicities will be evaluated.

NCT ID: NCT05056337 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Start date: August 1, 2021
Phase: Phase 3
Study type: Interventional

Study introduction: this is a multicenter, randomized controlled study of patients with histopathologically confirmed hepatocellular carcinoma (HCC) who have not previously received systematic treatment for HCC, all the patients are Chinese stage IIb/IIIa (BCLC stage B/C), and have not developed extrahepatic metastases. Follow-up, data collection and analysis will be performed for patients who meet the study inclusion criteria and will be treated with lenvatinib plus toripalimab and TACE (on demand) or TACE alone, so as to compare the objective response rate (ORR), overall survival (OS), progression-free survival (PFS), ratio of conversion resection, and safety between the two cohorts.

NCT ID: NCT05036434 Enrolling by invitation - Clinical trials for Adrenocortical Carcinoma

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

ACCOMPLISH
Start date: November 15, 2021
Phase: Phase 2
Study type: Interventional

- Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy - Trial Type : Single arm, prospective trial - Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) - Treatment Groups : Single arm - Number of trial participants : 30

NCT ID: NCT05007587 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma Stage IIIa

Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

Lenvatinib Plus Hepatic Arterial Infusion of Modified FOLFOX Regime vs Lenvatinib Plus Hepatic Arterial Infusion of Oxaliplatin Plus Raltitrexed in Patients with Advanced Hepatocellular Carcinoma